ROCKVILLE, MD, December 8, 2015 — Therabron Therapeutics, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory care, today presented a retrospective analysis of long-term follow-up data from a phase 1b trial of recombinant human CC10 protein (rhCC10) in premature infants at risk for chronic respiratory morbidity (CRM). The data were presented at the Hot Topics in Neonatology Annual Meeting being held December 6-8, 2015 in Washington, D.C.

For more information: Click Here.